US 11,925,683 B2
Compositions for making and using anti-Myostatin antibodies
Michelle Straub, Yarmouth, ME (US); Dong Yun Lee, Boston, MA (US); William K. McConaughy, Boston, MA (US); Katherine Jane Turner, Acton, MA (US); Nagesh K. Mahanthappa, Cambridge, MA (US); and Justin W. Jackson, Cambridge, MA (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Filed by SCHOLAR ROCK, INC., Cambridge, MA (US)
Filed on Sep. 3, 2021, as Appl. No. 17/446,897.
Application 17/446,897 is a continuation of application No. 16/374,854, filed on Apr. 4, 2019, granted, now 11,135,291.
Application 16/374,854 is a continuation of application No. 15/524,651, granted, now 10,307,480, issued on Jun. 4, 2019, previously published as PCT/US2015/059468, filed on Nov. 6, 2015.
Claims priority of provisional application 62/219,094, filed on Sep. 15, 2015.
Claims priority of provisional application 62/187,348, filed on Jul. 1, 2015.
Claims priority of provisional application 62/100,361, filed on Jan. 6, 2015.
Claims priority of provisional application 62/076,230, filed on Nov. 6, 2014.
Prior Publication US 2022/0152200 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); G01N 33/74 (2006.01); A61K 39/00 (2006.01); C07K 14/475 (2006.01)
CPC A61K 39/39533 (2013.01) [A61K 39/3955 (2013.01); C07K 16/22 (2013.01); G01N 33/53 (2013.01); G01N 33/74 (2013.01); A61K 2039/505 (2013.01); C07K 14/475 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2800/10 (2013.01)] 9 Claims
 
1. A host cell comprising a polynucleotide encoding an antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, binds to pro/latent myostatin with a decreased affinity at an acidic pH as compared to a neutral or physiological pH, and inhibits myostatin signaling after binding, wherein the host cell is prepared by the steps of:
(i) screening for an antibody or antigen-binding fragment that specifically binds to pro/latent myostatin as compared to mature myostatin and/or another member of the transforming growth factor beta family;
(ii) screening the antibody or antigen-binding fragment thereof for inhibition of myostatin signaling;
(iii) assaying the antibody or antigen-binding fragment for binding to pro/latent myostatin wherein the antibody or fragment binds to pro/latent myostatin with a decreased affinity at an acidic pH as compared to a neutral or physiological pH;
(iv) isolating a polynucleotide encoding the antibody or antigen-binding fragment; and
(v) incorporating the polynucleotide in the host cell.